We are Dedicated to
Biopharmaceutical
Research & Advancement

What We Do
Generex Biotechnology Corp., is a biopharmaceutical company that is actively involved in discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies.
News
  1. Generex Provides Summary of Ii-Key Hybrid Vaccine Platform
    August 7, 2017
    August 7, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen Express and Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer.
    READ MORE
  2. Generex Provides Summary of Ii-Key Hybrid Vaccine Platform Follow-Up to Antigen Express – Merck AE37 - KEYTRUDA® Collaboration
    September 20, 2017
    MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen Express and Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer.
    READ MORE
  3. Generex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in Chile
    September 12, 2017
    HDS embarking on multiple-product commercialization efforts MIRAMAR, Florida, September 12, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTC Pink:GNBTD) (www.generex.com) today announced that its subsidiary, Hema Diagnostic Systems LLC (www.hemadiagnosticsystems.com), has received an initial order for its Rapid 1-2-3® Hema HIV EXPRESS® from Diagnostiko Ltda. (www.diagnostiko.cl) in Chile.
    READ MORE
  4. Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
    July 31, 2017
    July 31, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.
    READ MORE